TABLE 7.

Inhibition constants (K_i) and IC₅₀ of inhibitors of C. albicans Sap2

Inhibitor	Sap2 Ki (nM)	IC50 (nM)	In vivo effects
Pepstatin	2.9a	27a	Protective effect in murine and rat mucosal models (45, 49). Lack of protection in murine disseminated-infection models (58, 64, 188, 258). Possible protection in murine peritonitis (117).
Ritonavir	300b	2,000a	Therapeutic effect in a rat vaginitis model (29).
Saquinavir	6,800b	300,000a	Not tested in vivo.
Indinavir	>106b	100,000a	Therapeutic effect in a rat vaginitis model (29).
A-70450	0.17a	1.4a	No protection in a murine disseminated-infection model (1, 227).
A-79912	NDc	3.8a	No protection in a murine disseminated-infection model (1, 227).
Peptidomimetics	0.6-14.4b	ND	Not tested in vivo.

^aValues from references 1 and 226. IC₅₀s of ritonavir, saquinavir, and indinavir are rough estimates based on data presented in reference 15.

^bValues from reference 168.

^cND, not determined.